Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome cancer biomarkers

Clinical Proteomics

Volumn 6, Issue 4, 2010, Pages 115-127

  Van Den Broek, Irene ^a   Sparidans, Rolf W ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Biomarker; Cancer; LC MS MS; Peptide; Protease activity; Sample handling

Indexed keywords

BIOLOGICAL MARKER; BRADYKININ DERIVATIVE; COMPLEMENT COMPONENT C4A; DES ARG9 BRADYKININ; FIBRINOGEN; FIBRINOGEN A ALPHA CHAIN; HYP3 BRADYKININ; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4; PEPTIDE; PEPTIDOME; PROTEINASE; PROTEOLYCTIC PEPTIDE; PROTEOME; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL TEMPERATURE; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; INCUBATION TEMPERATURE; LABORATORY DIAGNOSIS; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 78649719133     PISSN: 15426416     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12014-010-9054-z     Document Type: Article

References (38)

1. P Findeisen M Neumaier 2009 Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective Clin Chem Lab Med 47 666 84 1:CAS:528:DC%2BD1MXosFKrtLo%3D 10.1515/CCLM.2009.159 19445650
2. P Maurya P Meleady P Dowling M Clynes 2007 Proteomic approaches for serum biomarker discovery in cancer Anticancer Res 27 1247 55 1:CAS:528: DC%2BD2sXmslKju7s%3D 17593616
3. L Hu M Ye H Zou 2009 Recent advances in mass spectrometry-based peptidome analysis Expert Rev Proteomics 6 433 47 1:CAS:528:DC%2BD1MXhtVeitLzI 10.1586/epr.09.55 19681678
4. LA Liotta EF Petricoin 2006 Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold J Clin Invest 116 26 30 1:CAS:528:DC%2BD28XjslOisw%3D%3D 10.1172/JCI27467 16395400 (Pubitemid 43121786)
5. EF Petricoin C Belluco RP Araujo LA Liotta 2006 The blood peptidome: a higher dimension of information content for cancer biomarker discovery Nat Rev Cancer 6 961 7 1:CAS:528:DC%2BD28Xht1Clsr3L 10.1038/nrc2011 17093504 (Pubitemid 44862680)
6. AJ Cheng LC Chen KY Chien, et al. 2005 Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology Clin Chem 51 2236 44 1:CAS:528:DC%2BD2MXht1yks7fO 10.1373/clinchem.2005.052324 16239339 (Pubitemid 41692565)
7. ET Fung TT Yip L Lomas, et al. 2005 Classification of cancer types by measuring variants of host response proteins using SELDI serum assays Int J Cancer 115 783 9 1:CAS:528:DC%2BD2MXkvF2ksLw%3D 10.1002/ijc.20928 15704152 (Pubitemid 40776702)
8. Q Shi LN Harris X Lu, et al. 2006 Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery J Proteome Res 5 2947 55 1:CAS:528:DC%2BD28XhtVSnsbbN 10.1021/pr060099u 17081046 (Pubitemid 44749213)
9. J Song M Patel CN Rosenzweig, et al. 2006 Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay Clin Chem 52 1045 53 1:CAS:528:DC%2BD28XltlSrtb4%3D 10.1373/clinchem.2005.065722 16574760 (Pubitemid 43794416)
10. J Villanueva DR Shaffer J Philip, et al. 2006 Differential exoprotease activities confer tumor-specific serum peptidome patterns J Clin Invest 116 271 84 1:CAS:528:DC%2BD28XjslOgtQ%3D%3D 10.1172/JCI26022 16395409 (Pubitemid 43121812)
11. Z Zhang RC Bast Jr Y Yu, et al. 2004 Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer Cancer Res 64 5882 90 1:CAS:528:DC%2BD2cXmslaks7Y%3D 10.1158/0008-5472.CAN-04-0746 15313933 (Pubitemid 39095590)
12. JM Koomen LN Shih KR Coombes, et al. 2005 Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins Clin Cancer Res 11 1110 18 1:CAS:528:DC%2BD2MXht1ynt7w%3D 15709178
13. T Peccerella N Lukan R Hofheinz, et al. 2010 Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology Clin Chem 56 272 80 1:CAS:528:DC%2BC3cXhslaksb8%3D 10.1373/clinchem.2009.133462 20110451
14. MT Davis P Auger C Spahr SD Patterson 2007 Cancer biomarker discovery via low molecular weight serum proteome profiling - where is the tumor? Proteomics Clin Appl 1 1545 58 1:CAS:528:DC%2BD1cXmvA%3D%3D 10.1002/prca.200700141
15. Davis MT, Patterson SD. Does the serum peptidome reveal hemostatic dysregulation? Ernst Schering Res Found Workshop 2007:23-44
16. EP Diamandis 2006 Peptidomics for cancer diagnosis: present and future J Proteome Res 5 2079 82 1:CAS:528:DC%2BD28Xnt1Gnsrs%3D 10.1021/pr060225u 16944917 (Pubitemid 44330798)
17. AJ Rai CA Gelfand BC Haywood, et al. 2005 HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples Proteomics 5 3262 77 1:CAS:528:DC%2BD2MXps12it7k%3D 10.1002/pmic.200401245 16052621 (Pubitemid 41192034)
18. J Villanueva J Philip CA Chaparro, et al. 2005 Correcting common errors in identifying cancer-specific serum peptide signatures J Proteome Res 4 1060 72 1:CAS:528:DC%2BD2MXjtFehsLY%3D 10.1021/pr050034b 16083255 (Pubitemid 41208664)
19. M West-Norager CD Kelstrup C Schou EV Hogdall CK Hogdall NH Heegaard 2007 Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics J Chromatogr B Analyt Technol Biomed Life Sci 847 30 7 1:CAS:528:DC%2BD2sXhs1Cgsbw%3D 10.1016/j.jchromb.2006.09.048 17112795 (Pubitemid 46216199)
20. JYMN Engwegen M Alberts JC Knol, et al. 2008 Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer Proteomics Clin Appl 2 936 45 1:CAS:528:DC%2BD1cXotF2nsrg%3D 10.1002/prca.200780068 (Pubitemid 351943774)
21. SY Hsieh RK Chen YH Pan HL Lee 2006 Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling Proteomics 6 3189 98 1:CAS:528:DC%2BD28XlsFagt7Y%3D 10.1002/pmic.200500535 16586434 (Pubitemid 43806414)
22. JF Timms E Arslan-Low A Gentry-Maharaj, et al. 2007 Preanalytic influence of sample handling on SELDI-TOF serum protein profiles Clin Chem 53 645 56 1:CAS:528:DC%2BD2sXksFWhtb4%3D 10.1373/clinchem.2006.080101 17303688 (Pubitemid 46580234)
23. M West-Nielsen EV Hogdall E Marchiori CK Hogdall C Schou NH Heegaard 2005 Sample handling for mass spectrometric proteomic investigations of human sera Anal Chem 77 5114 23 1:CAS:528:DC%2BD2MXlsFKgsb4%3D 10.1021/ac050253g 16097747 (Pubitemid 41140826)
24. J Yi C Kim CA Gelfand 2007 Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma J Proteome Res 6 1768 81 1:CAS:528:DC%2BD2sXjvFKntrw%3D 10.1021/pr060550h 17411080 (Pubitemid 46814501)
25. H Umemura M Nezu Y Kodera, et al. 2009 Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Clin Chim Acta 406 179 80 1:CAS:528:DC%2BD1MXoslCqsLg%3D 10.1016/j.cca.2009.06. 007 19520068
26. I van den Broek RW Sparidans JH Schellens JH Beijnen 2008 Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum Rapid Commun Mass Spectrom 22 2915 28 10.1002/rcm.3695 18752334
27. 4-derived putative biomarker peptides in clinical serum samples Rapid Commun Mass Spectrom 24 1842 50 10.1002/rcm.4588 20533314
28. I van den Broek RW Sparidans JH Schellens JH Beijnen 2010 Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 878 590 602 10.1016/j.jchromb.2010.01.011 20116351
29. AWJ van Winden I van den Broek MCW Gast, et al. 2010 Serum degradome markers for the detection of breast cancer J Proteome Res 9 3781 8 10.1021/pr100395s 20557135
30. 4)-derived peptides in serum from breast cancer patients. Proteomics Clin Appl 2010; in press.
31. EW Davie K Fujikawa 1975 Basic mechanisms in blood coagulation Annu Rev Biochem 44 799 829 1:CAS:528:DyaE2MXltFWnu78%3D 10.1146/annurev.bi.44.070175. 004055 237463
32. MM Markiewski B Nilsson KN Ekdahl TE Mollnes JD Lambris 2007 Complement and coagulation: strangers or partners in crime? Trends Immunol 28 184 92 1:CAS:528:DC%2BD2sXjslGrtbg%3D 10.1016/j.it.2007.02.006 17336159 (Pubitemid 46476881)
33. AP Kaplan M Silverberg 1987 The coagulation-kinin pathway of human plasma Blood 70 1 15 1:CAS:528:DyaL2sXkvFCjsrY%3D 3297198
34. P Marshall O Heudi S McKeown A Amour F Abou-Shakra 2002 Study of bradykinin metabolism in human and rat plasma by liquid chromatography with inductively coupled plasma mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry Rapid Commun Mass Spectrom 16 220 8 1:CAS:528:DC%2BD38Xht1CjtLs%3D 10.1002/rcm.565 11803544 (Pubitemid 34118005)
35. H Nishimura I Kakizaki T Muta, et al. 1995 cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein FEBS Lett 357 207 11 1:CAS:528:DyaK2MXjtVSmtbk%3D 10.1016/0014-5793(94)01364-7 7805892
36. JM Koomen D Li LC Xiao, et al. 2005 Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery J Proteome Res 4 972 81 1:CAS:528:DC%2BD2MXkt1Kltr0%3D 10.1021/pr050046x 15952745 (Pubitemid 40863287)
37. K Saguchi T Tobe K Hashimoto, et al. 1995 Cloning and characterization of cDNA for inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP), a novel human plasma glycoprotein J Biochem 117 14 18 1:CAS:528:DyaK2MXktVCmtLs%3D 7775381
38. NCBI: (C4a), NP-002209 (ITIH4), NP-000499 (Fibrinogen-α), P010422 (HMW kininogen). http://wwwncbinlmnihgov/entrez/viewerfcgi?val=NP-009224 March 2010.